History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and affects millions worldwide. Due to the lack of effective systemic therapies for HCC, researchers have been investigating the use of locoregional tumor control with Yttrium-90 (Y90) radioembolization since the 1960s. F...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-01-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | http://www.mdpi.com/2077-0383/8/1/55 |
id |
doaj-50498757986a42e891c7f29f2851dadf |
---|---|
record_format |
Article |
spelling |
doaj-50498757986a42e891c7f29f2851dadf2020-11-24T21:24:39ZengMDPI AGJournal of Clinical Medicine2077-03832019-01-01815510.3390/jcm8010055jcm8010055History and Evolution of Yttrium-90 Radioembolization for Hepatocellular CarcinomaAman Saini0Alex Wallace1Sadeer Alzubaidi2M. Grace Knuttinen3Sailendra Naidu4Rahul Sheth5Hassan Albadawi6Rahmi Oklu7Division of Vascular and Interventional Radiology, Laboratory for Minimally Invasive Therapeutics, Mayo Clinic, Phoenix, AZ 85054, USADivision of Vascular and Interventional Radiology, Laboratory for Minimally Invasive Therapeutics, Mayo Clinic, Phoenix, AZ 85054, USADivision of Vascular and Interventional Radiology, Laboratory for Minimally Invasive Therapeutics, Mayo Clinic, Phoenix, AZ 85054, USADivision of Vascular and Interventional Radiology, Laboratory for Minimally Invasive Therapeutics, Mayo Clinic, Phoenix, AZ 85054, USADivision of Vascular and Interventional Radiology, Laboratory for Minimally Invasive Therapeutics, Mayo Clinic, Phoenix, AZ 85054, USADepartment of Interventional Radiology, MD Anderson Cancer Center, Houston, TX 77054, USADivision of Vascular and Interventional Radiology, Laboratory for Minimally Invasive Therapeutics, Mayo Clinic, Phoenix, AZ 85054, USADivision of Vascular and Interventional Radiology, Laboratory for Minimally Invasive Therapeutics, Mayo Clinic, Phoenix, AZ 85054, USAHepatocellular carcinoma (HCC) is the most common form of primary liver cancer and affects millions worldwide. Due to the lack of effective systemic therapies for HCC, researchers have been investigating the use of locoregional tumor control with Yttrium-90 (Y90) radioembolization since the 1960s. Following the development of glass and resin Y90 microspheres in the early 1990s, Y90 radioembolization has been shown to be a safe and efficacious treatment for patients with HCC across Barcelona Clinic Liver Cancer (BCLC) stages. By demonstrating durable local control, good long term outcomes, and equivalent if not superior tumor responses and tolerability when compared to alternative therapies including transarterial chemoembolization (TACE) and sorafenib, Y90 radioembolization is being increasingly used in HCC treatment. More recently, investigations into variations in Y90 radioembolization technique including radiation segmentectomy and radiation lobectomy have further expanded its clinical utility. Here, we discuss the history and evolution of Y90 use in HCC. We outline key clinical trials that have established the safety and efficacy of Y90 radioembolization, and also summarize trials comparing its efficacy to existing HCC treatments. We conclude by reviewing the techniques of radiation segmentectomy and lobectomy, and by discussing dosimetry.http://www.mdpi.com/2077-0383/8/1/55Yttrium-90Y90radioembolizationhepatocellular carcinomaHCCliver cancer |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Aman Saini Alex Wallace Sadeer Alzubaidi M. Grace Knuttinen Sailendra Naidu Rahul Sheth Hassan Albadawi Rahmi Oklu |
spellingShingle |
Aman Saini Alex Wallace Sadeer Alzubaidi M. Grace Knuttinen Sailendra Naidu Rahul Sheth Hassan Albadawi Rahmi Oklu History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma Journal of Clinical Medicine Yttrium-90 Y90 radioembolization hepatocellular carcinoma HCC liver cancer |
author_facet |
Aman Saini Alex Wallace Sadeer Alzubaidi M. Grace Knuttinen Sailendra Naidu Rahul Sheth Hassan Albadawi Rahmi Oklu |
author_sort |
Aman Saini |
title |
History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma |
title_short |
History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma |
title_full |
History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma |
title_fullStr |
History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma |
title_full_unstemmed |
History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma |
title_sort |
history and evolution of yttrium-90 radioembolization for hepatocellular carcinoma |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2019-01-01 |
description |
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and affects millions worldwide. Due to the lack of effective systemic therapies for HCC, researchers have been investigating the use of locoregional tumor control with Yttrium-90 (Y90) radioembolization since the 1960s. Following the development of glass and resin Y90 microspheres in the early 1990s, Y90 radioembolization has been shown to be a safe and efficacious treatment for patients with HCC across Barcelona Clinic Liver Cancer (BCLC) stages. By demonstrating durable local control, good long term outcomes, and equivalent if not superior tumor responses and tolerability when compared to alternative therapies including transarterial chemoembolization (TACE) and sorafenib, Y90 radioembolization is being increasingly used in HCC treatment. More recently, investigations into variations in Y90 radioembolization technique including radiation segmentectomy and radiation lobectomy have further expanded its clinical utility. Here, we discuss the history and evolution of Y90 use in HCC. We outline key clinical trials that have established the safety and efficacy of Y90 radioembolization, and also summarize trials comparing its efficacy to existing HCC treatments. We conclude by reviewing the techniques of radiation segmentectomy and lobectomy, and by discussing dosimetry. |
topic |
Yttrium-90 Y90 radioembolization hepatocellular carcinoma HCC liver cancer |
url |
http://www.mdpi.com/2077-0383/8/1/55 |
work_keys_str_mv |
AT amansaini historyandevolutionofyttrium90radioembolizationforhepatocellularcarcinoma AT alexwallace historyandevolutionofyttrium90radioembolizationforhepatocellularcarcinoma AT sadeeralzubaidi historyandevolutionofyttrium90radioembolizationforhepatocellularcarcinoma AT mgraceknuttinen historyandevolutionofyttrium90radioembolizationforhepatocellularcarcinoma AT sailendranaidu historyandevolutionofyttrium90radioembolizationforhepatocellularcarcinoma AT rahulsheth historyandevolutionofyttrium90radioembolizationforhepatocellularcarcinoma AT hassanalbadawi historyandevolutionofyttrium90radioembolizationforhepatocellularcarcinoma AT rahmioklu historyandevolutionofyttrium90radioembolizationforhepatocellularcarcinoma |
_version_ |
1725987043251585024 |